SCHEMBL2804192

SCHEMBL2804192

CCS(=O)(=O)c1ccc(-c2n[nH]c3ncc4c(c23)CCN(C(=O)Nc2ccccc2)C4)cc1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 8/20 0.43
NAMPT P43490 8/20 0.43
NPC1 O15118 4/20 0.42
RAB9A P51151 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TP53 P04637 1/20 0.42
THRB P10828 1/20 0.41
ATM Q13315 1/20 0.40
PRKDC P78527 1/20 0.40
ATR Q13535 1/20 0.40
PDGFRB P09619 1/20 0.39
BRD4 O60885 1/20 0.38
CREBBP Q92793 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TAS1R3 Q7RTX0 1/20 0.38
TAS1R1 Q7RTX1 1/20 0.38
TAS1R2 Q8TE23 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2512524 0.89 NPC1 (0.51) ROCK2NAMPTNPC1RAB9ASMN1; SMN2
SCHEMBL2805950 0.84 NAMPT (0.47) ROCK2NAMPTNPC1RAB9ASMN1; SMN2
SCHEMBL2488267 0.81 NPC1 (0.47) ROCK2NAMPTNPC1RAB9ASMN1; SMN2
SCHEMBL2804580 0.80 FAAH (0.47) ROCK2NAMPTNPC1RAB9ASMN1; SMN2
SCHEMBL2805115 0.80 NPC1 (0.53) NAMPTNPC1RAB9ATHRBTAS1R3
SCHEMBL2803991 0.80 NAMPT (0.44) ROCK2NAMPTNPC1RAB9ASMN1; SMN2
SCHEMBL2803749 0.79 THRB (0.53) ROCK2NAMPTNPC1RAB9ASMN1; SMN2
SCHEMBL2809552 0.79 RAB9A (0.44) ROCK2NAMPTNPC1RAB9ASMN1; SMN2
SCHEMBL2804159 0.78 TRPV1 (0.49) ROCK2NAMPTNPC1RAB9ASMN1; SMN2
SCHEMBL2803761 0.78 RAB9A (0.52) ROCK2NAMPTNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 ROCK2 1391/4885NAMPT 212/4885NPC1 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.